SLShun Lu

Shun Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects

Research Interests


Shun Lu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Hong Jian

    Shanghai Lung Tumor Clinical Medical Center Shanghai Chest Hospital Shanghai Jiao Tong University China

    1 shared publication
  • Yi Yang

    Shanghai Lung Tumor Clinical Medical Center Shanghai Chest Hospital Shanghai Jiao Tong University China

    1 shared publication
  • Yi Zhao

    Shanghai Lung Tumor Clinical Medical Center Shanghai Chest Hospital Shanghai Jiao Tong University China

    1 shared publication
  • Yunhua Xu

    Shanghai Lung Tumor Clinical Medical Center Shanghai Chest Hospital Shanghai Jiao Tong University China

    1 shared publication

Latest Publications

  • Open Access

    AZD0530 sensitizes drug‐resistantALK‐positive lung cancer cells by inhibitingSRCsignaling

    by Yi Zhao, Yi Yang, Yunhua Xu, Shun Lu, Hong Jian

    Most tumors develop resistance to targeted cancer drugs, even though these drugs have produced substantial clinical responses. Here we established anaplastic lymphoma kinase (ALK)‐positive drug‐resistant lung cancer cell lines, which are resistant to ceritinib (LDK378). We found that ceritinib treatment resulted in robust upregulation ofSRCactivity, as measured by the phosphorylation of theSRCsubstrate paxillin. Knockdown ofSRCalone with siRNAeffectively sensitized ceritinib resistance inALK‐positive cells. Furthermore,SRCinhibition byAZD0530 was effective inALK‐resistant cancer cells. Thus,ALKinhibition by ceritinib may lead to upregulation ofSRCsignaling, andAZD0530 could serve as a potential drug in the clinic to treatALK‐resistant lung cancer patients.